Melbourne Australia - Starpharma Holdings Ltd (ASX: SPL; OTCQX: SPHRY) today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 June 2013.

The cash balance at 30 June 2013 was $33.8 million, a net cash burn of $9.0 million for the year. This result includes the $5.4 million R&D tax incentive refund received by the company in the March quarter.  

During the year Starpharma reported positive Phase 2 trial results for VivaGel^® for prevention of recurrent bacterial vaginosis (R-BV) supporting its progression into Phase 3, key advances in Starpharma’s dendrimer-docetaxel development in preparation for human trials later this year, as well as new partnerships with AstraZeneca for oncology and in agrochemicals with Makhteshim Agan.

“This year has seen significant progress across Starpharma’s entire product portfolio, including completion of some key clinical trials for VivaGel^®, advancement of VivaGel^® as a condom coating with our commercial partners, as well as drug delivery and agrochemical applications, in both internal and partnership programs.  The company has closed the year in a very solid financial position and with a number of important milestones anticipated in the months ahead,” Starpharma CEO Dr Jackie Fairley said. 

Download ASX Announcement: Appendix 4C - Quarterly Cashflow Report ( pdf file, 141kb)